Welcome to our dedicated page for Biostax news (Ticker: BTAX), a resource for investors and traders seeking the latest updates and insights on Biostax stock.
Biostax Corp (BTAX) delivers innovative immunotherapies targeting chronic diseases through its patented low dose naltrexone and methionine-enkephalin platforms. This news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and strategic developments.
Access timely reports on clinical trial progress, regulatory milestones, and research partnerships that demonstrate Biostax's commitment to immune restoration therapies. Our curated news collection simplifies tracking of manufacturing expansions, intellectual property developments, and key collaborations with medical institutions.
Discover updates spanning therapeutic innovations, business strategy shifts, and peer-reviewed research findings. All content undergoes rigorous verification to ensure alignment with Biostax's focus on evidence-based immune system modulation and chronic disease management solutions.
Bookmark this page for streamlined access to Biostax's latest developments in specialty pharmaceuticals. Return regularly for authoritative reporting on immunotherapy advancements that balance scientific complexity with investor-focused clarity.
Biostax Corp (BIOX) has announced its decision to voluntarily delist from the OTC Pink marketplace and deregister from the SEC, following 76.4% shareholder approval through a Joint Written Consent. The company plans to file Form 25 with the SEC on March 15, 2025, with delisting becoming effective ten days later.
The company will simultaneously file Form 15 to deregister its common stock under the Securities Exchange Act of 1934. Management believes the current public market valuation doesn't reflect their achievements and potential, and operating as a private company will provide greater flexibility and reduce administrative costs.
Biostax's pipeline includes JKB-122, which has received FDA authorization for clinical trials in Autoimmune Hepatitis for newly diagnosed patients and Phase 2 trials for NASH and NAFLD. The company also plans an IND filing for JKB-122 as an adjunct therapy in HIV treatment.
FAQ
What is the current stock price of Biostax (BTAX)?
What is the market cap of Biostax (BTAX)?
